Ingen Enters Hospital and Therapy Markets With Expected Revenue Increase
CEO Live Radio Broadcast Talks About These New Markets
- Press Release
- Source: Ingen Technologies, Inc.
- On 4:15 pm EST, Friday November 20, 2009
YUCAIPA, Calif., Nov. 20, 2009 (GLOBE NEWSWIRE) -- Ingen Technologies, Inc. (Pink Sheets:
IGNT -
News), a leading global Medical Device Manufacturer focused on the $4B Respiratory market with their Oxyview products for the growing aging population and emerging markets for Home (DME), Hospital and Aviation industries, announced today that the company is now marketing direct to the hospital and therapy respiratory markets. Ingen's CEO, Scott Sand, will discuss these new markets this coming Tuesday, November 24, 2009 at 11:34AM eastern standard time on The Money Channel's American Scene Radio with host Steve Crowley.
Related Quotes
SymbolPriceChange
IGNT.PK0.000.00
{"s" : "ignt.pk","k" : "c10,l10,p20,t10","o" : "","j" : ""}
According to the most recent report published in June 2009 and made available on the Global Market Research Information Network, respiratory market revenues are high currently, with good potential for sales increases. As the patient population grows and respiratory diseases become more prevalent, the market has the potential for continued growth in many countries and therapeutic areas. There is a great demand for products that provide therapeutic and commercial benefits in this demanding and competitive market. The developing markets of Asia, Latin America and Europe will drive sales increases in particular.
The company is introducing its new Oxyview Nasal Cannula at the America Association of Respiratory Care (AARC) on December 5 - 7, 2009 as an exhibitor. There are 47,000 members of AARC who are hospital based clinicians, therapists and managers, and a large majority will be attending this annual meeting in San Antonio, Texas.
"Our focus has been home health care markets and this is going very smoothly with an increase in sales from home oxygen patients and oxygen providers. Our GSA application is expected to be approved in the near future, and with the growing hospital markets in respiratory care, the Oxyview Nasal Cannula will be an attractive device for hospital nursing as it has shown to save time and provide additional assurance of oxygen flow. Our near final ISO Certification expected in late December 2009 and our recent issue/publication of our patent in the People's Republic of China is in alignment with the future demand for our Oxyview Nasal Cannula in various export countries according to the most recent studies," stated Scott Sand, Chief Executive Officer and Chairman of the Board.
http://www.electronics-ca.com/products/World-Respiratory-Disorders-Market.html
http://www.moneychannel.tv/scas.php
http://www.aarc.org/
http://www.medox-oxyview.com/
www.ingen-tech.com
About Ingen: Ingen is an established medical device manufacturer with an emerging new medical product line for the respiratory market worth an estimated $4 Billion in the US, and $8 billion globally. The company introduced Oxyview into the respiratory market in late 2007 after securing US and Foreign Patents and successful licensing with the Food & Drug Administration, and has commenced domestic and global distribution with manufacture representative organizations and OEM partners. In 2009, the company introduced the new Oxyview Nasal Cannula for adult, children and infants, with issued patents in China and the USA, and pending patents in Japan, Canada and European Communities expected to be issued in 2010. In addition to selling its respiratory products within the global medical industry, the company is selling the same products within other industries that include aviation, automotive, emergency response, military and government transportation. The company holds a Device Manufacturing License with the State of California, Department of Public Health, Food and Drug Branch as it manufacturers all of its respiratory products in the United States. There are 32 million US patients with Chronic Obstructive Pulmonary Disease (COPD), and 600 million patients worldwide. Ingen Technologies is now the largest manufacturer of in-line gravity-independent oxygen flow meters.
The Ingen Technologies, Inc. logo is available at
http://www.globenewswire.com/newsroom/prs/?pkgid=2472
Safe Harbor for Forward-Looking Statements: This news release includes forward-looking statements. While these statements are made to convey to the public the company's progress, business opportunities and growth prospects, readers are cautioned that such forward-looking statements represent management's opinion. Whereas management believes such representations to be true and accurate based on information and data available to the company at this time, actual results may differ materially from those described. The company's operations and business prospects are always subject to risk and uncertainties. Important factors that may cause actual results to differ are and will be set forth in the company's periodic filings with the U.S. Securities and Exchange Commission.
Linear Mode
